View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Thijs Berkelder
  • Thijs Berkelder
Tijs Hollestelle
  • Tijs Hollestelle

Sif Group/Finally - something positive/BUY

Sif stated it reached its production target of four monopiles per week in December and reiterated its FY25 EBITDA guidance, expecting €45m. This indicates c.€18m 4Q EBITDA, up versus c.€14m in 3Q. Sif's focus is now on increasing efficiency into 1H26. Sif also repeated its FY26 EBITDA guidance, expecting €135m. Given the unreliable prior guidance, we cut our FY26 EBITDA estimate to €97.7m, aiming 28% below the guidance. Sif already arranged a waiver for its 4Q25 and 1Q26 bank covenants and we es...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Randstad: Preliminary preview of 4Q25F results, due 11 February; Sif Group: Implied 4Q EBITDA c.€18m, up vs 3Q c.€14m

Glanbia: 1 director

A director at Glanbia sold 3,500 shares at 14.680EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...

Dermapharm Holding SE: 1 director

A director at Dermapharm Holding SE bought 1,438,000 shares at 37.430EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Fastned/Ongoing bond raises, a lot more is needed/HOLD

Fastned's 3Q25 trading update showed charging volume growth picked up slightly vs prior quarters but remains below BEV penetration growth. We modestly raise volume estimates yet expect growth to slow and stay under BEV penetration levels and stay uncomfortable on the significant funding gap. We maintain our HOLD rating and lift our target price to €20.50 per share (from €20).

Fatma Agnès Hamdani
  • Fatma Agnès Hamdani
Fatma Agnès Hamdani
  • Fatma Agnès Hamdani

Koninklijke BAM Group N.V.: 1 director

A director at Koninklijke BAM Group N.V. maiden bought 50,000 shares at 7.460EUR and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adyen: Preview Investor Day Aperam: In line 3Q25 EBITDA, soft 4Q25 guidance balanced by optimism on EU trade action and FCF beat Brunel: 3Q25 beats; outlook FY25 in line but trend NL and cash position weaker CM.com: Rejects Bird's offer Euronext: Records, beats, buybacks and upgrades GBL: 3Q25 a bit light Kinepolis: Canadian peer Cineplex 3Q25 Results and October 2025 Box office revenue NEPI Rockcastle: COO appointed as new CEO Proximus: Major cut to Global 2026 EBITDA, in line 3Q, 2025 FCF guid...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch